Vivos Therapeutics closes acquisition of SOD Sciences stake and 50% interest in pseudohypoxia test
VVOS•Vivos Therapeutics closed its acquisition of a stake in SOD Sciences and a 50% interest in a pseudohypoxia test, opening a potential path to access more than 325,000 new patients through the AHA channel.
1. Acquisition closed
Vivos Therapeutics said it closed its acquisition of a stake in SOD Sciences and a 50% interest in a pseudohypoxia test. The company said the deal opens a potential path to access more than 325,000 new patients through the AHA channel.
